Natural history of self-reported symptoms following SARS-CoV-2 infection: A target trial emulation in a prospective community-recruited cohort
Authors:
Open Access
- 23 January 2026
- journal article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 164, 108422
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Division of Intramural Research (UH3AI133675)
- National Institutes of Health
- City University of New York
- National Institute of Allergy and Infectious Diseases
This publication has 38 references indexed in Scilit:
- Symptom burden and post-COVID-19 syndrome 24 months following SARS-CoV-2 infection: Longitudinal population-based studyJournal of Infection, 2025
- Self-Reported Everyday Functioning After COVID-19 InfectionJAMA Network Open, 2024
- Development of a Definition of Postacute Sequelae of SARS-CoV-2 InfectionJAMA, 2023
- Long COVID and rehabilitationJournal of the Formosan Medical Association, 2023
- 1.5 years pandemic – Psychological burden over the course of the COVID-19 pandemic in Germany: A nine-wave longitudinal community studyJournal of Affective Disorders, 2022
- Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort studyThe Lancet, 2022
- Presence of SARS-CoV-2 antibodies following COVID-19 diagnosis: a longitudinal study of patients at a major urgent care provider in New YorkDiagnostic Microbiology and Infectious Disease, 2022
- Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort studyEuropean Journal of Internal Medicine, 2021
- Electronic medical records can be used to emulate target trials of sustained treatment strategiesJournal of Clinical Epidemiology, 2018
- Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analysesJournal of Clinical Epidemiology, 2016